Drug Monograph
Paliperidone
Invega (oral ER) · Invega Sustenna (1-month LAI) · Invega Trinza (3-month LAI) · Invega Hafyera (6-month LAI)
Pharmacokinetic Profile
Half-Life
~23 h (oral ER); 25–49 days (LAI)
Metabolism
Minimal hepatic; ~59% renally excreted unchanged
Protein Binding
74%
Bioavailability
28% (oral ER); 100% (IM)
Volume of Distribution
487 L
Clinical Information
Drug Class
Second-generation (atypical) antipsychotic
Available Doses
Oral ER: 1.5, 3, 6, 9 mg tablets
Route
Oral; Intramuscular (deltoid/gluteal)
Renal Adjustment
Required
Hepatic Adjustment
None (mild–moderate)
Pregnancy
Risk of neonatal EPS with 3rd-trimester use
Lactation
Excreted in breast milk; weigh risks vs benefits
Schedule
Not a controlled substance
Generic Available
Yes (oral ER)
Black Box Warning
Yes — Elderly dementia mortality
Indications for Paliperidone
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Schizophrenia | Adults; Adolescents 12–17 years | Monotherapy | FDA Approved |
| Schizoaffective disorder | Adults (≥18 years) | Monotherapy or adjunctive to mood stabilizers/antidepressants | FDA Approved |
Paliperidone is the primary active metabolite of risperidone and carries FDA approval for both schizophrenia and schizoaffective disorder. The oral extended-release formulation uses an OROS osmotic delivery system that provides controlled drug release over 24 hours, reducing peak-to-trough plasma fluctuation compared to immediate-release antipsychotics. Long-acting injectable formulations (monthly, 3-month, and 6-month) are approved exclusively for schizophrenia after the patient has been stabilized on shorter-acting paliperidone formulations.
Off-Label Uses
Bipolar I disorder — acute mania (evidence quality: moderate): Some clinicians use paliperidone ER as adjunctive therapy in acute manic or mixed episodes based on its pharmacological similarity to risperidone, which carries FDA approval for bipolar mania.
Psychosis in Parkinson’s disease (evidence quality: low): Limited case series exist, though use requires extreme caution given increased sensitivity to antipsychotics in this population.
Dosing for Paliperidone
Oral Extended-Release (Invega) — Adult & Adolescent Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Schizophrenia — adult, new diagnosis or acute exacerbation | 6 mg once daily | 3–12 mg/day | 12 mg/day | No initial titration required; increase in 3 mg increments at intervals >5 days Can be taken with or without food; swallow whole |
| Schizophrenia — adolescent 12–17 yr, weight <51 kg | 3 mg once daily | 3–6 mg/day | 6 mg/day | No clear benefit at higher doses in adolescent trials Adverse effects are dose-related in this population |
| Schizophrenia — adolescent 12–17 yr, weight ≥51 kg | 3 mg once daily | 3–12 mg/day | 12 mg/day | Increase in 3 mg increments at intervals >5 days |
| Schizoaffective disorder — adult, acute episode | 6 mg once daily | 3–12 mg/day | 12 mg/day | May be used as monotherapy or with mood stabilizers/antidepressants Adjust at intervals >4 days in 3 mg steps |
| Schizophrenia — relapse prevention (maintenance) | Continue dose that achieved stability | 12 mg/day | Use lowest effective dose; reassess periodically | |
Renal & Hepatic Dose Adjustments (Oral ER)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Mild renal impairment (CrCl 50–80 mL/min) | 3 mg once daily | 3–6 mg/day | 6 mg/day | Half-life extends to ~24 h |
| Moderate–severe renal impairment (CrCl 10–50 mL/min) | 1.5 mg once daily | 1.5–3 mg/day | 3 mg/day | Half-life extends to ~40–51 h Not recommended if CrCl <10 mL/min |
| Mild–moderate hepatic impairment (Child-Pugh A/B) | No adjustment needed | Not studied in severe hepatic impairment | ||
Long-Acting Injectable — Invega Sustenna (Monthly)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Schizophrenia or schizoaffective disorder — initiation | 234 mg IM (Day 1) + 156 mg IM (Day 8) | 117 mg IM monthly | 234 mg/month | Both initiation doses must be in the deltoid; maintenance in deltoid or gluteal Establish oral tolerability first if antipsychotic-naive |
| Mild renal impairment (CrCl 50–80 mL/min) | 156 mg (Day 1) + 117 mg (Day 8) | 78 mg IM monthly | 78 mg/month | Both initiation doses in deltoid Not recommended if CrCl <50 mL/min |
Clinical Pearl: Oral-to-Injectable Transition
Patients switching from oral paliperidone ER to Invega Sustenna can begin the injectable when their next oral dose is due. Previous oral antipsychotics may be gradually discontinued at treatment initiation. The initiation regimen (234 mg + 156 mg) is designed to rapidly achieve therapeutic plasma concentrations without need for oral supplementation.
Pharmacology of Paliperidone
Mechanism of Action
Paliperidone (9-hydroxyrisperidone) is a centrally active dopamine D2 and serotonin 5-HT2A receptor antagonist. This dual blockade is thought to underlie its antipsychotic efficacy: D2 antagonism in mesolimbic pathways reduces positive symptoms such as hallucinations and delusions, while 5-HT2A antagonism in cortical regions may improve negative symptoms and reduce EPS risk relative to first-generation agents. Paliperidone also blocks alpha-1 and alpha-2 adrenergic receptors, contributing to orthostatic hypotension, and histamine H1 receptors, which may cause sedation and weight gain. Unlike its parent compound risperidone, paliperidone undergoes minimal hepatic metabolism, resulting in a pharmacokinetic profile that is largely independent of CYP2D6 polymorphisms.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral ER: 28% bioavailability; Tmax ~24 h; food increases Cmax/AUC by 50–60% | OROS delivery system provides steady absorption over 24 h with minimal peak-trough fluctuation; clinical trials were conducted without regard to food |
| Distribution | Vd = 487 L; protein binding 74% | Extensive tissue distribution; lower protein binding than risperidone (90%) means paliperidone is less susceptible to displacement interactions |
| Metabolism | Limited hepatic metabolism; four minor pathways identified (dealkylation, hydroxylation, dehydrogenation, benzisoxazole scission); none CYP-predominant | Low CYP-mediated interaction risk; no dose adjustment for CYP2D6 poor metabolizers; no hepatic adjustment for mild–moderate impairment |
| Elimination | 59% excreted unchanged in urine; ~80% total in urine, ~11% in faeces; t½ ~23 h (oral ER) | Renal function is the primary determinant of clearance; dose reduction is mandatory in renal impairment |
Side Effects of Paliperidone
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Extrapyramidal symptoms (composite) | up to 23% | Dose-related; includes dystonia, tremor, rigidity, parkinsonism; higher at 9–12 mg doses |
| Somnolence / Sedation | up to 26% | Usually attenuates within 1–2 weeks of continued therapy; warn about driving |
| Akathisia | up to 17% | Dose-related; distinguish from psychotic agitation; may respond to dose reduction or propranolol |
| Tachycardia | up to 15% | Includes sinus tachycardia; generally mild and not requiring discontinuation |
| Headache | up to 14% | Typically self-limiting; not dose-related in clinical trials |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Weight gain (≥7% body weight increase) | 6–9% | Lower at 3–6 mg (6–7%); higher at 9–12 mg (9%); less than olanzapine but warrants monitoring |
| Insomnia | 5–8% | Comparable to placebo in some trials; consider dosing in the morning if disruptive |
| Anxiety | 4–8% | Distinguish from akathisia; may improve with dose stabilization |
| Dizziness | 3–6% | Related to alpha-1 blockade; advise slow postural changes |
| Dyspepsia / Nausea | 3–5% | OROS shell visible in stool is normal; reassure patients |
| Constipation | 3–5% | Anticholinergic component is low; dietary measures usually sufficient |
| Orthostatic hypotension | 2–5% | More common at initiation; monitor in cardiovascular disease |
| Nasopharyngitis | 3–6% | Reported more frequently in schizoaffective disorder trials |
| Hyperprolactinaemia (symptomatic) | 1–4% | Prolactin elevation is dose-dependent and often asymptomatic; galactorrhoea, amenorrhoea, gynaecomastia may occur |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Neuroleptic malignant syndrome (NMS) | Very rare | Days to weeks after initiation or dose change | Immediate discontinuation; intensive supportive care; monitor CK, renal function |
| QT prolongation | 3–5% (QTc increase) | Dose-dependent; steady-state | Obtain baseline ECG; avoid co-prescription with other QT-prolonging agents; correct electrolytes |
| Tardive dyskinesia | Rare; risk increases with duration | Months to years of treatment | Consider discontinuation; assess risk-benefit of continued therapy; refer for valbenazine or deutetrabenazine if persistent |
| Hyperglycaemia / New-onset diabetes | Uncommon | Weeks to months | Monitor fasting glucose and HbA1c; manage per ADA standards if abnormal |
| Seizures | 0.2% | Any time; more likely with seizure history | Reassess therapy; lower dose or switch agent; ensure seizure threshold-lowering factors addressed |
| Agranulocytosis / Severe neutropenia | Very rare | First few months | Discontinue if ANC <1000/mm³; monitor CBC frequently in patients with pre-existing low WBC |
| Priapism | Rare (postmarketing) | Any time | Urological emergency; permanent discontinuation |
| Anaphylaxis / Angioedema | Very rare | Any time (often early in treatment) | Discontinue permanently; emergency treatment per protocol |
Discontinuation
Discontinuation Rates
Adults (Schizophrenia, Oral ER)
~10% vs ~6% placebo
Top reasons: Nervous system disorders (EPS, somnolence, akathisia)
Adults (Schizoaffective, Oral ER)
~8% vs ~5% placebo
Top reasons: Gastrointestinal disorders, EPS
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Nervous system disorders (composite) | ~2% | Most common reason in adult schizophrenia trials; dose-related |
| Gastrointestinal disorders | ~1.5% | Leading reason in schizoaffective disorder trials |
| Psychiatric worsening | ~1% | Similar rate to placebo; may reflect underlying disease |
Managing Hyperprolactinaemia
Paliperidone consistently elevates prolactin levels due to D2 blockade in the tuberoinfundibular pathway. In pivotal trials, prolactin-related adverse events occurred in approximately 1–4% of patients. Clinicians should inquire about menstrual irregularities, galactorrhoea, sexual dysfunction, and breast tenderness at each visit. If symptomatic hyperprolactinaemia develops, options include dose reduction, switching to a prolactin-sparing antipsychotic (e.g. aripiprazole, quetiapine), or adding low-dose aripiprazole as adjunctive therapy to lower prolactin.
Drug Interactions with Paliperidone
Paliperidone undergoes minimal CYP-mediated hepatic metabolism, which confers a lower overall drug interaction burden than most antipsychotics. However, renal elimination via P-glycoprotein transport and modest QT effects create clinically important interactions with specific drug classes.
Major
Carbamazepine
MechanismStrong CYP3A4/P-gp induction increases renal clearance of paliperidone by ~35%
EffectReduces paliperidone AUC by ~37%; risk of subtherapeutic levels
ManagementRe-evaluate paliperidone dose on initiation/discontinuation of carbamazepine; may need to increase oral dose up to 12 mg/day. Avoid strong inducers during LAI dosing interval.
FDA PI
Major
QT-Prolonging Agents
MechanismAdditive QTc prolongation (paliperidone increases QTcLD by ~7–12 msec at therapeutic-to-supratherapeutic doses)
EffectIncreased risk of torsades de pointes and sudden cardiac death
ManagementAvoid Class IA/III antiarrhythmics, thioridazine, chlorpromazine, moxifloxacin. Correct hypokalaemia/hypomagnesaemia. Obtain ECG if combination unavoidable.
FDA PI
Moderate
Divalproex Sodium / Valproate
MechanismValproate increases paliperidone Cmax and AUC by approximately 50% through unknown mechanism
EffectHigher paliperidone exposure; increased risk of dose-dependent adverse effects (EPS, prolactin elevation)
ManagementMonitor for increased side effects; consider reducing paliperidone dose. No valproate dose adjustment needed.
FDA PI
Moderate
Risperidone
MechanismPaliperidone is the active metabolite of risperidone; co-administration produces additive paliperidone exposure
EffectPotential for supratherapeutic paliperidone levels with enhanced toxicity
ManagementAvoid concomitant use; if switching, allow appropriate washout based on formulation half-life.
FDA PI
Moderate
Levodopa / Dopamine Agonists
MechanismPharmacological antagonism at D2 receptors
EffectMutual attenuation of therapeutic effects
ManagementAvoid in Parkinson’s disease; use pimavanserin or quetiapine for psychosis in PD if needed.
FDA PI
Moderate
CNS Depressants / Alcohol
MechanismAdditive CNS depression
EffectEnhanced sedation, dizziness, impaired psychomotor function, increased fall risk
ManagementCounsel patients to avoid alcohol; use caution with benzodiazepines, opioids, sedating antihistamines.
FDA PI
Moderate
Antihypertensives
MechanismAdditive hypotensive effect via alpha-1 adrenergic blockade
EffectIncreased risk of orthostatic hypotension and syncope
ManagementMonitor blood pressure; adjust antihypertensive doses as needed.
FDA PI
Minor
Lithium
MechanismNo significant pharmacokinetic interaction demonstrated in clinical studies
EffectNo clinically meaningful change in paliperidone or lithium levels
ManagementNo dose adjustment required for either agent; standard lithium monitoring continues.
FDA PIMonitoring for Paliperidone
-
Metabolic Panel
Baseline, 12 wk, then annually
Routine Fasting glucose, HbA1c, lipid panel. Atypical antipsychotics carry metabolic risk; paliperidone has intermediate metabolic liability (lower than olanzapine, similar to risperidone). -
Body Weight & BMI
Baseline, monthly for 3 months, then quarterly
Routine Track weight gain trajectory; intervene early with dietary/exercise counselling if ≥7% gain. -
Renal Function
Baseline, then annually
Routine Serum creatinine and estimated CrCl. Critical for paliperidone given predominant renal elimination; dose adjustment required if CrCl declines below 80 mL/min. -
ECG
Baseline; repeat if QT risk factors present
Trigger-based Assess QTc interval. Indicated at baseline and if adding QT-prolonging medications, or in patients with cardiac history, electrolyte abnormalities, or bradycardia. -
Prolactin Level
If symptoms arise
Trigger-based Check if galactorrhoea, amenorrhoea, sexual dysfunction, or gynaecomastia develop. Paliperidone consistently raises prolactin; symptomatic management may require dose reduction or switch. -
CBC with Differential
Baseline; frequently in first months if pre-existing low WBC
Trigger-based Monitor for leukopenia/neutropenia; discontinue paliperidone if ANC falls below 1000/mm³ without another identifiable cause. -
EPS Assessment
Each visit
Routine Use AIMS for tardive dyskinesia screening at least every 6 months in adults, every 3 months in elderly. Evaluate for akathisia, parkinsonism, and dystonia at each visit. -
Blood Pressure
Baseline, then at each visit
Routine Orthostatic vitals at initiation and dose changes. Alpha-1 blockade may cause symptomatic postural hypotension, particularly in the elderly or those on antihypertensives.
Contraindications & Cautions for Paliperidone
Absolute Contraindications
- Known hypersensitivity to paliperidone, risperidone, or any excipient in the formulation. Cross-reactivity exists because paliperidone is risperidone’s active metabolite; anaphylaxis and angioedema have been reported with both agents.
Relative Contraindications (Specialist Input Recommended)
- Congenital long QT syndrome or history of cardiac arrhythmia — risk of torsades de pointes; specialist cardiology input needed if antipsychotic is essential.
- Dementia with Lewy bodies or Parkinson’s disease — increased sensitivity to antipsychotics with severe EPS, postural instability, and NMS-like reactions.
- Severe renal impairment (CrCl <10 mL/min) — not studied; use not recommended.
- Severe hepatic impairment — not studied; risk-benefit discussion required.
- Pre-existing GI narrowing (oral ER only) — OROS non-deformable tablet may cause obstruction in patients with strictures, Crohn’s disease, or short gut syndrome.
Use with Caution
- Patients at risk for aspiration pneumonia (dysphagia, advanced age)
- History of seizures or conditions lowering seizure threshold
- Cardiovascular or cerebrovascular disease (orthostatic hypotension risk)
- Diabetes or metabolic syndrome risk factors
- Patients exposed to temperature extremes (impaired thermoregulation)
- Elderly patients (increased sensitivity to orthostatic effects, EPS, falls)
FDA Boxed Warning
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration 10 weeks) in patients taking atypical antipsychotics revealed a risk of death 1.6 to 1.7 times that of placebo-treated patients. Deaths were primarily cardiovascular or infectious in nature. Paliperidone is not approved for dementia-related psychosis.
Patient Counselling for Paliperidone
Purpose of Therapy
Paliperidone helps manage symptoms of schizophrenia and schizoaffective disorder by restoring the balance of certain brain chemicals. It does not cure the condition but can reduce hallucinations, disordered thinking, agitation, and mood instability when taken consistently. Stopping the medication without medical guidance increases the risk of relapse.
How to Take
Swallow the extended-release tablet whole — it must not be chewed, crushed, or split. The tablet uses a special delivery system, and its shell may appear in the stool, which is normal. Take the tablet at the same time each day. Clinical trials were conducted without regard to food, but food may increase drug absorption; consistency is more important than whether the patient eats with the dose.
Drowsiness & Dizziness
Tell patientSedation is most noticeable in the first 1–2 weeks and usually improves with continued use. Avoid driving or operating heavy machinery until you know how the medication affects you. Rise slowly from sitting or lying positions to reduce dizziness.
Call prescriberIf you faint, fall, or experience persistent dizziness that interferes with daily activities beyond the first two weeks.
Movement Problems (EPS)
Tell patientYou may notice muscle stiffness, tremor, restlessness, or involuntary movements. These effects are often dose-related and can be managed with dose adjustment or additional medication.
Call prescriberIf you develop severe muscle rigidity, high fever, confusion, or rapid heartbeat (possible NMS), or persistent uncontrollable movements of the face or tongue (possible tardive dyskinesia).
Weight Gain & Metabolic Effects
Tell patientSome patients gain weight on paliperidone. Regular exercise and a balanced diet help manage this. Your doctor will monitor your blood sugar, cholesterol, and weight periodically.
Call prescriberIf you develop excessive thirst, frequent urination, blurred vision, or unexplained weight gain exceeding 5 kg, as these may signal blood sugar changes.
Hormonal Effects (Prolactin)
Tell patientThis medication may raise prolactin levels, which can cause missed periods, breast swelling or discharge, or sexual difficulties. These effects are reversible with dose adjustment or medication change.
Call prescriberIf you experience persistent menstrual changes, breast discharge, or troubling sexual side effects.
Heat Sensitivity
Tell patientPaliperidone can impair your body’s ability to regulate temperature. Stay well-hydrated, avoid prolonged sun exposure or strenuous exercise in hot weather, and seek cool environments when possible.
Call prescriberIf you experience signs of heat-related illness such as confusion, rapid breathing, or inability to sweat.
Tablet Shell in Stool
Tell patientIt is normal to see a tablet-shaped object in your stool. The medication has already been absorbed; what you see is the empty shell from the delivery system.
Call prescriberNot necessary unless you regularly see multiple intact tablets, which may suggest a GI transit issue.
Sources
Regulatory (PI / SmPC)
- INVEGA (paliperidone) Extended-Release Tablets. Full Prescribing Information. Janssen Pharmaceuticals, Inc. Revised 01/2019. FDA Label Primary source for oral ER dosing, indications, adverse reactions, and pharmacokinetics.
- INVEGA SUSTENNA (paliperidone palmitate) Extended-Release Injectable Suspension. Full Prescribing Information. Janssen Pharmaceuticals, Inc. Revised 09/2024. FDA Label Primary source for monthly LAI dosing, renal adjustments, and injection-specific adverse reactions.
- INVEGA TRINZA (paliperidone palmitate) Extended-Release Injectable Suspension. Full Prescribing Information. Janssen Pharmaceuticals, Inc. DailyMed Source for 3-month LAI formulation dosing and transition from monthly to quarterly injection.
Key Clinical Trials
- Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1-3):147-161. DOI Pivotal phase 3 fixed-dose trial establishing efficacy of paliperidone ER 6, 9, and 12 mg in adult schizophrenia.
- Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363-1370. DOI Second pivotal trial supporting efficacy across paliperidone ER dose range in schizophrenia.
- Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-117. DOI Key relapse-prevention trial for paliperidone palmitate monthly injection versus placebo.
- Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-561. DOI PRIDE study comparing paliperidone LAI with oral antipsychotics; source for real-world discontinuation and adverse event data.
Guidelines
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. 3rd ed. 2020. DOI APA guideline positioning second-generation antipsychotics, including paliperidone, as first-line treatment for schizophrenia.
- Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Schizophrenia. Am J Psychiatry. 2020;177(9):868-872. DOI Summary of APA guideline recommendations on LAI antipsychotic use for adherence-challenged patients.
Mechanistic / Basic Science
- Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and temporal cortical 5-HT2A receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008;197(2):229-235. DOI PET imaging study characterising D2 and 5-HT2A receptor occupancy across paliperidone ER dose range.
Pharmacokinetics / Special Populations
- Boom S, Talluri K, Engelen S, et al. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opin Drug Metab Toxicol. 2012;8(5):651-661. DOI Comprehensive pharmacokinetic review covering OROS delivery, ADME, renal impairment data, and food effects.
- Shimizu T, Hata T, Mimura M, et al. Population pharmacokinetics of paliperidone palmitate (once-monthly formulation) in Japanese, Korean, and Taiwanese patients with schizophrenia. Clin Pharmacol Drug Dev. 2020;9(4):469-481. DOI Population PK analysis confirming paliperidone palmitate LAI pharmacokinetics across East Asian populations.